 NEW YORK, March 17, 2022 GLOBE NEWSWIRE -- Indaptus Therapeutics, Inc. Nasdaq: INDP Indaptus or the Company, today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific Officer, will present and participate in a panel discussion at the 3rd Annual STING TLR-Targeting Therapies Summit taking place virtually from March 22-24, 2022. 